May 13, 2024 -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company advancing disease-modifying therapies to transform the treatment of kidney disease, today announced that it has entered into a research collaboration with Primula Group to lever a large body of genetic data on patients living with chronic kidney disease (CKD), including insights from close to 500,000 individuals in the UK Biobank. The study will be led by Dipender Gill, M.D. Ph.D., who is based at